Dr Kopetz discusses the value of ctDNA assays, trials that have shown prognostic implications with this type of assay, and the future of ctDNA research.
Biomarker Consortium
Advertisement
Dr Dietrich discusses the rationale for testing for HER2 and MET mutations in patients with NSCLC, as well as best practices for implementing this testing.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
Five Under 5: Top Oncology Videos for the Week of 1/25
5